Bill Newell, Sutro Biopharma CEO (Sutro via YouTube)
December 4, 2020 07:32 AM EST
R&D

Sutro's con­tin­ued PhI da­ta read­outs in­di­cate im­prov­ing re­sponse in ovar­i­an can­cer. What's next?

Max Gelman

Senior Editor

Just a few months af­ter its last in­ter­im read­out, Sutro Bio­phar­ma $STRO is shar­ing more Phase I da­ta in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times